The information on this website is exactly that, for information purposes only. This information is not intended to be a substitute for sound medical advice or for seeing a physician. Patients should always consult with their physician before starting any medical treatment. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
An Amazing New Discovery
Evidence Based Practice
PCABioScience is a biotechnical company devoted to research and development. The company was founded by Dr. Lanny Johnson, a medical doctor. Dr. Johnson is an orthopedic surgeon and therefore the initial focus was on orthopedic-related conditions. This work led to additional discoveries affecting one’s general health and wellness; to related areas of health management with nutraceuticals and food supplements.
His concern for medical conditions still not fully understood or those ineffectively treated continues to motivate him to explore potential possibilities. Although schooled and practiced traditional medicine and surgery he was not closed to any possibility to improve the human condition; through nutraceuticals.
In 2005 he read a newspaper article about how the dyes of cherries caused animal pancreas cells to produce more insulin. He reasoned that perhaps human cells would respond with stimulation in a similar manner and produce a local growth factor. Experiments at an independent contract biotech laboratory in La Jolla, California confirmed his hypothesis. The dyes that make cherries red applied to the human joint lining in tissue culture produced a growth hormone, IGF-1 that was long known to heal cartilage. The first of many United States patents were sought.
By 2022 he has been granted 21 such US patents related to this primary dye and its metabolites. His intellectual property now includes; antibiotics, wound healing, wrinkle treatment, acne treatment, protection of food during processing and delivery, and more recently a means of treating COVID-19.
Our vision sees his work as not only a novel therapeutic but the basis for an entirely new industry based on its many known applications and those yet to be discovered.
Our focus has been on the health potential for protocatechuic acid (PCA). PCA is safe. PCA is found throughout nature. Small amounts are in the soil, rivers and ponds, trees, plants, plus fruits and vegetables. PCA is common to the human diet. It is readily absorbed upon ingestion. It is produced in small amounts by the bacterial in the human large bowel.
The therapeutical potential is dose dependent when applied to various cells, tissues and organs. PCA’s therapeutic potential exists for orthopedic conditions including bone and cartilage healing and control of surgical infections.
There is basic science evidence that PCA acts as a disease modifying osteoarthritic drug (DMOAD). There being no DMOAD, a patent is pending.
We have independent laboratory evidence that PCA has potential to reduce surgical site infections (SSI). SSI have serious consequences beyond the morbidity. Reported in the literature, but overlooked is the 25% 5-year mortality following an infected total joint surgery. The mortality is greater than that of cancer of the breast or prostate. Application has been made to the FDA to initiating clinical trials for treatment of infected total joints.
Another observation, again known but not widely acknowledged is the “persister” microbes and the adverse effect on SSI. A single application of skin disinfectant will not kill all the bacteria. Within 20 minutes the persister pathogen bacteria colonies have reemerged. There is basic science evidence PCA has potential to address this problem. A EPA application has been in process for last 5 years, the long duration related to the EPA inefficiency.
With the advent of COVID19, our attention turned to PCA’s potential for treatment of virus. We learned by literature review and independent contract laboratory studies that PCA inactivates SARS CoV-1 virus. The method of action is known. The results indicate that other encapsulated viruses would have the same fate: HIV, Flu, Ebola, etc. These specific applications are under study.
To further support the wide use of PCA, it was learned that the Candida auris, a terrible pathogen was vulnerable to a PCA related compound. A US patent has been granted. Studies are underway at major medical center.
Equally amazing was while working on PCA for COVID19 we learned one of the complications in India of such is the Black Fungus. Independent laboratory testing showed that PCA has potential use against this fatal complication which often requires the removal of the patient’s infected eyes.
The intent at present is to translate the basic science findings to clinical medicine.